- Previous Close
0.7959 - Open
0.8405 - Bid --
- Ask --
- Day's Range
0.7100 - 0.8869 - 52 Week Range
0.4600 - 4.4400 - Volume
1,018,705 - Avg. Volume
673,703 - Market Cap (intraday)
1.812B - Beta (5Y Monthly) 1.59
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6200 - Earnings Date Mar 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.67
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
prokidney.comRecent News: PROK
View More
Performance Overview: PROK
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PROK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PROK
View MoreValuation Measures
Market Cap
102.45M
Enterprise Value
-252.61M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.02k
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.87%
Return on Equity (ttm)
-41.20%
Revenue (ttm)
76k
Net Income Avi to Common (ttm)
-61.19M
Diluted EPS (ttm)
-0.6200
Balance Sheet and Cash Flow
Total Cash (mrq)
358.29M
Total Debt/Equity (mrq)
0.81%
Levered Free Cash Flow (ttm)
-121.36M